Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study (DECAPUB)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00909844 |
Recruitment Status
:
Completed
First Posted
: May 29, 2009
Results First Posted
: May 1, 2017
Last Update Posted
: May 1, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Precocious Puberty | Drug: Triptorelin (I.N.N.) | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 35 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty |
Study Start Date : | April 2008 |
Actual Primary Completion Date : | April 2015 |
Actual Study Completion Date : | January 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Triptorelin |
Drug: Triptorelin (I.N.N.)
Decapeptyl® SR 11.25mg
|
- Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0) [ Time Frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months) ]The primary objective was to assess efficacy of triptorelin pamoate 11.25 mg with respect to percentage of children maintaining a regression or stabilisation of sexual maturity (based on Tanner breast [girls] or genital [boys] pubertal stage) until end of study. Study treatment lasted until end of the therapeutic period; visits for Months 36 and 48 were optional since a child may have already finished the study at a prior visit. The Final Visit only occurred if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Results are presented only for percentage of girls with regression or stabilisation of Tanner breast pubertal stage (n=34). Since only one boy was included in the study, results for this outcome measure were listed only and no statistical analysis was performed. Please also note additional post-hoc analysis for regression or stabilisation of Tanner breast pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.
- Percentage of Patients With a Suppressed Luteinizing Hormone (LH) Response to Gonadotropin-Releasing Hormone (GnRH) Test [ Time Frame: Months -6, 0 and 36 ]A suppressed LH response to the GnRH test was defined as a stimulated peak of LH ≤3 international units per litre (IU/L). Percentage of patients who had a suppressed LH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
- Levels of Oestradiol in Girls or Testosterone in Boys Both Measured by Radioimmunoassay (RIA) [ Time Frame: Months -6, 0, 12, 36 and Final Visit (up to 63 months) ]Mean levels of oestradiol in girls or testosterone in boys are reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
- Percentage of Patients With a Suppressed Follicle Stimulating Hormone (FSH) Response to GnRH Test [ Time Frame: Months -6, 0 and 36 ]A suppressed FSH response to the GnRH test was defined as a stimulated peak of FSH ≤3 IU/L. Percentage of patients who had a suppressed FSH response to the GnRH test is reported. It should be noted that almost no hormonal data was collected after Baseline; all data analysed is presented.
- Body Mass Index (BMI) for Chronological Age Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]Mean changes of BMI from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- BMI Standard Deviation (SD) Score for Chronological Age Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]Mean changes of BMI SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Auxological Parameters Variations: Height SD Score [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]Mean changes of height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Auxological Parameters Variations: Growth Velocity SD Score [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]Mean changes of growth velocity SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Auxological Parameters Variations: Weight Variation [ Time Frame: Months -6, 0, 12, 24, 36, 48 and Final Visit (up to 63 months) ]Mean changes of weight from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Predicted Adult Height SD Score [ Time Frame: Months -6, 0, 12 and Final Visit (up to 63 months) ]Mean change of predicted adult height SD score from Pretreatment and from Baseline are reported. SD score is a standard term used in growth studies and represents standard deviations calculated as the patient value minus the mean divided by the SD. SD scores vary depending on the age and sex of the child. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented. Also note that data for this endpoint was analysed for girls only.
- Bone Age Maturation [ Time Frame: Months -6, 0 and Final Visit (up to 63 months) ]Mean change in difference between bone age and chronological age from Pretreatment and from Baseline are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Percentage of Girls With a Uterine Length < 36 Millimetres (mm) [ Time Frame: Months -6, 0, 12, 24, 36 and Final Visit (up to 63 months) ]Percentage of girls who had a uterine length < 36 mm are reported. It should be noted that only limited patient data was collected after Baseline; all data analysed is presented.
- Percentage of Children With a Stabilisation or Regression of Tanner Pubic Hair Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0) [ Time Frame: Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months) ]Pubic hair was measured by the Tanner method on a scale of 1 to 6. A low grade (i.e. 1) corresponds to a pre-pubertal stage and a high grade (i.e. 5 or 6) to an adult stage. Percentage of patients who had stabilisation or regression (no change in grade or a reduced grade) of Tanner pubic hair pubertal stage is reported. Study treatment was to last until the end of the therapeutic period; visits for Months 36 and 48 were optional because if the girl was already 11 and the boy already 13, they would have finished the study at a prior visit. The Final Visit was to occur only if the child did not end the study by a complete visit such as at Months 24, 36 or 48. Please also note the additional post-hoc analysis for percentage of children with a stabilisation or regression of Tanner pubic hair pubertal stage which applied the variable Last Visit on Treatment instead of Final Visit.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The child must have completed study 2-54-52014-143
- The child must have an effective response to 2 injections of triptorelin 11.25 mg according to investigator's evaluation with no significant treatment side effects
Exclusion Criteria:
- The patient has a known hypersensitivity to any of the test materials or related compounds
- The patient is unable or unwilling to comply fully with the protocol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00909844
France | |
Hôpital Hôtel Dieu (CHU) | |
Angers, France, 49033 | |
Medical Centre | |
Bordeaux, France, 33000 | |
Hôpital Flaubert | |
Le Havre, France, 76083 | |
Hôpital Archet II | |
Nice, France, 06202 | |
Hôpital Robert Debré | |
Paris, France, 75019 | |
American Memorial Hospital | |
Reims, France, 51092 | |
Hôpital Charles Nicolle | |
Rouen, France, 76031 | |
Hôpital Hautepierre | |
Strasbourg, France, 67100 | |
Hôpital de la Gespe | |
Tarbes, France, 65013 | |
Hôpital des Enfants | |
Toulouse, France, 31026 |
Study Director: | Olivier GATTOLLIAT, MD | Ipsen |
Responsible Party: | Ipsen |
ClinicalTrials.gov Identifier: | NCT00909844 History of Changes |
Other Study ID Numbers: |
2-54-52014-159 2008-000565-39 ( EudraCT Number ) |
First Posted: | May 29, 2009 Key Record Dates |
Results First Posted: | May 1, 2017 |
Last Update Posted: | May 1, 2017 |
Last Verified: | March 2017 |
Additional relevant MeSH terms:
Puberty, Precocious Gonadal Disorders Endocrine System Diseases Triptorelin Pamoate Luteolytic Agents Contraceptive Agents, Female |
Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents |